Cargando…

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study

BACKGROUND: Direct oral anticoagulants (DOACs) do not require concentration monitoring. However, whether DOAC concentrations are stable and their variation between and within patients is not well studied. METHODS: Patients on vitamin K antagonists (VKA) who switched to rivaroxaban, apixaban, or dabi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toorop, Myrthe M. A., van Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., van der Meer, Felix J. M., Cannegieter, Suzanne C., Lijfering, Willem M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	HAEMOSTASIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297950/ https://www.ncbi.nlm.nih.gov/pubmed/34664401 http://dx.doi.org/10.1111/jth.15563

Ejemplares similares

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda D., et al.
Publicado: (2021)

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2023)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
por: Buijs, Jeroen T., et al.
Publicado: (2019)

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
por: Khialani, Deeksha, et al.
Publicado: (2020)

Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case‐control study
por: Li‐Gao, Ruifang, et al.
Publicado: (2018)

Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis
por: van den Boom, Bente P., et al.
Publicado: (2021)

Efficacy of pro‐ and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery
por: Bos, Sarah, et al.
Publicado: (2020)

Kallikrein augments the anticoagulant function of the protein C system in thrombin generation
por: Wan, Jun, et al.
Publicado: (2021)

Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study
por: Toorop, Myrthe M A, et al.
Publicado: (2021)

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin‐K antagonists: A randomized controlled trial
por: Mertens, Bram J., et al.
Publicado: (2019)

Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study
por: Orsi, Fernanda A., et al.
Publicado: (2021)

SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
por: Cnossen, Marjon H., et al.
Publicado: (2022)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2022)

Von Willebrand disease type 2M: Correlation between genotype and phenotype
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2021)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
por: Punt, Marieke C., et al.
Publicado: (2020)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial
por: Schol‐Gelok, Suzanne, et al.
Publicado: (2020)

Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2022)

A clinical prediction score for transient versus persistent childhood immune thrombocytopenia
por: Schmidt, David E., et al.
Publicado: (2020)

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Coagulopathy signature precedes and predicts severity of end‐organ heat stroke pathology in a mouse model
por: Proctor, Elizabeth A., et al.
Publicado: (2020)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease
por: von Meijenfeldt, Fien A., et al.
Publicado: (2020)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Characterization of laboratory coagulation parameters and risk factors for intraventricular hemorrhage in extremely premature neonates
por: Roberts, Jonathan C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ev86adc2isafvgrmmnmj1qt71c